8th Congress of the International Boiron Society
8th of may, 2019
Heidelberg, Germany
Professor Rachel Nechuchstai of the Hebrew University in Jerusalem presented at the 8th Congress of the International Boiron Society in May a lecture entitled “The liability of the NEET proteins’ iron sulphur cluster: biomedical implications”. Professor Nechuchstai presented data generated in part through the close collaboration with ENYO Pharma on this topic.
EASL (European Association for the Study of the Liver)
10-14 April, 2019
Vienna, Austria
ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.
The Mitochondrial Biogenesis and Dynamics in Health and Disease Conference
19-24 May, 2019
PalmSpring, California, USA
ENYO Pharma will be present at The Mitochondrial Biogenesis and Dynamics in Health and Disease Conference meeting from the 19th to the 24th of May at Palm Spring and presented a poster on the topic: “Chemical targeting of NEET/CISDs proteins reveals the central role of mitochondrial morphodynamics regulation in viral infection”.
MIMESIS Newsletter #4: A novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #4, December 2018
After two years, ENYO Pharma’s EU funded MIMESIS project was a real success and has delivered several promising new drug development starting points most significantly for RSV and ICD.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”.
Latest Press Release 